关于三阴性乳腺癌 (TNBC) 自的全球研究现状和前沿:全面的文献计量和可视化分析
Hongyi Liang1, Hanhan Chen2, Guangxi Shi2
1Shandong University of Traditional Chinese Medicine, Jinan, 250014, Shandong, China.
Discover oncology
|November 21, 2025
概括
本文献分析揭示了三阴性乳腺癌 (TNBC) 自研究的关键趋势. 中国在出版方面处于领先地位,越来越关注自.
科学领域:
- 生物医学科学 生物医学科学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 三阴性乳腺癌 (TNBC) 仍然是一个具有挑战性的亚型,目标治疗有限.
- 自是一种细胞降解过程,在TNBC的发展和治疗反应中起着复杂的作用.
- 了解TNBC中自的研究环境对于推进治疗策略至关重要.
研究的目的:
- 综合评估TNBC中自研究的演变和知识结构.
- 通过图书统计分析确定领先的国家,机构和关键研究主题.
- 精确指出这个领域的新兴前沿和未来的研究方向.
主要方法:
- 在TNBC中对523篇关于自的论文进行了图书统计引文分析,来自Web of Science核心集合 (2015-2024).
- 使用VOS浏览器和CiteSpace来分析出版数据,协作和关键字趋势.
- 审查了来自国家,机构,作者和期刊的贡献.
主要成果:
- 中国是最大的出版国,与美国有着重要的合作关系.
- 研究重点包括自的机制,其对TNBC的影响,以及相关的基因/蛋白质.
- 在TNBC中自和耐药性已经成为一个关键的研究前沿.
结论:
- 这项研究提供了TNBC (2015-2024) 中自研究的第一个文献统计概述.
- 它巩固了当前的知识,并突出了新兴趋势,为研究人员和临床医生提供了宝贵的见解.
- 这些发现为未来对TNBC的自性向疗法的研究奠定了基础.
相关概念视频
Autophagy
5.6K
Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
5.6K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
The Nucleolus
10.2K
The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
10.2K
PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K


